Cross-sectional and longitudinal analysis of an oxidative stress biomarker for spinal and bulbar muscular atrophy

Muscle and Nerve

Volumn 46, Issue 5, 2012, Pages 692-697

  Mano, Tomoo ^a   Katsuno, Masahisa ^a   Banno, Haruhiko ^a,b   Suzuki, Keisuke ^a   Suga, Noriaki ^a   Hashizume, Atsushi ^a   Tanaka, Fumiaki ^a   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Androgen receptor; Biomarker; Motor neuron; Oxidative stress; Spinal and bulbar muscular atrophy

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; GENOMIC DNA;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; FOLLOW UP; HUMAN; KENNEDY DISEASE; LONGITUDINAL STUDY; MALE; MOTOR PERFORMANCE; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; URINALYSIS; URINE LEVEL; WALKING;

ADULT; AGED; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DEOXYGUANOSINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUSCULAR DISORDERS, ATROPHIC; OXIDATIVE STRESS;

EID: 84867375038     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23413     Document Type: Article

References (44)

1. Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset: a sex-linked recessive trait, Neurology 1968; 18: 671-680.
2. Sperfeld AD, Karitzky J, Brummer D, Schreiber H, Häussler J, Ludolph AC, et al. X-linked bulbospinal neuronopathy: Kennedy disease. Arch Neurol 2002; 59: 1921-1926.
3. Fischbeck KH. Kennedy disease. J Inherit Metab Dis 1997; 20: 152-158.
4. Atsuta N, Watanabe H, Ito M, Banno H, Suzuki K, Katsuno M, et al. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 2006; 129: 1446-1455.
5. Andrew SE, Goldberg YP, Hayden MR. Rethinking genotype and phenotype correlations in polyglutamine expansion disorders. Hum Mol Genet 1997; 6: 2005-2010.
6. La Spada AR, Taylor JP. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet 2010; 11: 247-258.
7. Katsuno M, Adachi H, Waza M, Banno H, Suzuki K, Tanaka F, et al. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA). Exp Neurol 2006; 200: 8-18.
8. Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi T, et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 2003; 9: 768-773.
9. Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Yabe I, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 875-884.
10. Fernández-Rhodes LE, Kokkinis AD, White MJ, Watts CA, Auh S, Jeffries NO, et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol 2011; 10: 140-147.
11. Banno H, Adachi H, Katsuno M, Suzuki K, Astuta N, Watanabe H, et al. Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker. Ann Neurol 2006; 59: 520-526.
12. Suzuki K, Katsuno M, Banno H, Takeuchi Y, Kawashima M, Suga N, et al. The profile of motor unit number estimation (MUNE) in spinal and bulbar muscular atrophy. J Neurol Neurosurg Psychiatry 2010; 81: 567-571.
13. Martin LJ. DNA damage and repair: relevance to mechanisms of neurodegeneration. J Neuropathol Exp Neurol 2008; 67: 377-387.
14. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59-69.
15. Browne SE. Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Ann NY Acad Sci 2008; 1147: 358-382.
16. Ranganathan S, Harmison GG, Meyertholen K, Pennuto M, Burnett BG, Fischbeck KH. Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum Mol Genet 2009; 18: 27-42.
17. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997; 69: 1196-1203.
18. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
19. Takeuchi Y, Katsuno M, Banno H, Suzuki K, Kawashima M, Atsuta N, et al. Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve 2008; 38: 964-971.
20. Morillas-Ruiz J, Zafrilla P, Almar M, Cuevas MJ, López FJ, Abellán P, et al. The effects of an antioxidant-supplemented beverage on exercise-induced oxidative stress: results from a placebo-controlled double-blind study in cyclists. Eur J Appl Physiol 2005; 95: 543-549.
21. Muñoz ME, Galan AI, Palacios E, Diez MA, Muguerza B, Cobaleda C, et al. Effect of an antioxidant functional food beverage on exercise-induced oxidative stress: a long-term and large-scale clinical intervention study. Toxicology 2010; 28: 101-111.
22. Saito S, Yamauchi H, Hasui Y, Kurashige J, Ochi H, Yoshida K. Quantitative determination of urinary 8-hydroxydeoxyguanosine (8-OH-dg) by using ELISA. Res Commun Mol Pathol Pharmacol 2000; 107: 39-44.
23. Doyu M, Sobue G, Mukai E, Kachi T, Yasuda T, Mitsuma T, et al. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 1992; 32: 707-710.
24. Dejager S, Bry-Gauillard H, Bruckert E, Eymard B, Salachas F, LeGuern E, et al. A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab 2002; 87: 3893-3901.
25. Nakanishi S, Suzuki G, Kusunoki Y, Yamane K, Egusa G, Kohno N. Increasing of oxidative stress from mitochondria in type 2 diabetic patients. Diabetes Metab Res Rev 2004; 20: 399-404.
26. Kimura S, Yamauchi H, Hibino Y, Iwamoto M, Sera K, Ogino K. Evaluation of urinary 8-hydroxydeoxyguanine in healthy Japanese people. Basic Clin Pharmacol Toxicol 2006; 98: 496-502.
27. Yu P, Wang Z, Sun X, Chen X, Zeng S, Chen L, et al. Hydrogen-rich medium protects human skin fibroblasts from high glucose or mannitol induced oxidative damage. Biochem Biophys Res Commun 2011; 409: 350-355.
28. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999; 52: 562-565.
29. Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, et al. Creatine in Huntington's disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG. Neurology 2006; 66: 250-252.
30. Casadesus G, Smith MA, Basu S, Hua J, Capobianco DE, Siedlak SL, et al. Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer's disease. Mol Neurodegen 2007; 2: 2.
31. Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, et al. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 2002; 9: 244-248.
32. Hirayama M, Nakamura T, Watanabe H, Uchida K, Hama T, Hara T, et al. Parkinsonism Relat Disord 2011; 17: 46-49.
33. Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011; 10: 377-393.
34. Liu Y, Prasad R, Beard WA, Hou EW, Horton JK, McMurray CT, et al. Coordination between polymerase beta and FEN1 can modulate CAG repeat expansion. J Biol Chem 2009; 284: 28352-28366.
35. Su S, Jou S, Cheng W, Lin T, Li J, Huang C, et al. Mitochondrial DNA damage in spinal and bulbar muscular atrophy patients and carriers. Clin Chim Acta 2010; 411: 626-630.
36. Young JE, Garden GA, Martinez RA, Tanaka F, Sandoval CM, Smith AC, et al. Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk. J Neurosci 2009; 18: 1987-1997.
37. Sato S, Mizuno Y, Hattori N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 2005; 64: 1081-1083.
38. Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler 2008; 9: 177-183.
39. Tong L, Wan M, Zhou D, Gao J, Zhu Y, Bi K. LC-MS/MS determination and pharmacokinetic study of albiflorin and paeoniflorin in rat plasma after oral administration of Radix Paeoniae Alba extract and Tang-Min-Ling-Wan. Biomed Chromatogr 2010; 24: 1324-1331.
40. Hashizume A, Katsuno M, Banno H, Suzuki K, Suga N, Tanaka F, et al. Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy. J Neurol 2012; 259: 712-719.
41. Katsuno M, Tanaka F, Sobue G. Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases J Neurol Neurosurg Psychiatry 2012; 83: 329-335.
42. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010; 9: 560-574.
43. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007; 6: 878-886.
44. Boesch S, Sturm B, Hering S, Scheiber-Mojdehkar B, Steinkellner H, Goldenberg H, et al. Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial. Mov Disord 2008; 23: 1940-1944.